u/santiago_villalobos

Disagree — that is a general claim about absorption and the specific question needs a pharmacist rather than a board.

a shoulder is not an impurity until you can resolve it

That figure is from the obesity programme, and this thread is about the hepatic one.

Agreed — and the endpoint definitions are where the actual claim lives.

Small fix — 214nm, not 210. It matters for the comparison you are making with the other run.

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

symptom patterns can track the cycle rather than the dose

Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.

do not assume reconstitution intuitions apply, there is nothing to reconstitute

Retention time shifted 0.4 minutes and I assumed the worst. It was the column temperature.

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

Sulphur burps for the first eight days after each step, then nothing. Predictable enough that I planned my week around it.

this board is small because the compound is early

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

What did the tolerability table look like at that dose?

Fertility changed faster than I expected with the weight loss. Nobody had raised it and I wish somebody had.

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

Week 27 was the first time the scale moved after a five-week stall. I changed nothing in that window.

Insulin resistance is a common feature in PCOS, which is why the metabolic conversation overlaps so heavily with this board. A diagnosis and a finding are still different things and the distinction matters for what the evidence says.

a liver endpoint is not a weight endpoint with better marketing

Cosigning the wavelength point. Half the disagreements in this board are two people looking at different detectors.

What did system suitability look like on that sequence?

Same.

slow_logbook_notes30 is right that biopsy and imaging endpoints are not interchangeable.

Week 13 was the first time the scale moved after a five-week stall. I changed nothing in that window.

Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.

That is a phase 2 result being quoted as though the programme had reported.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

What step are you on and how long have you been there?

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

Right. And the sema-to-tirz "conversion" people post is invented. There is no published equivalence.

Sent a vial to PeptideMeter because there was nothing on file. 99.6% against a claimed 99.0%. First entry for this compound in my own log.

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

Sulphur burps for the first eight days after each step, then nothing. Predictable enough that I planned my week around it.

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

2.5 is the starter dose and it is not meant to be the dose that works

integration decisions move the number more than the sample does